Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space

 
• By Alaric DeArment
  
Editorial use only - ARCADIA, CA - MAR 20: Horses break from the gate in an allowance race at Santa Anita Park on Mar 20, 2010 in Arcadia, CA
Mustang Bio announced data from the Phase I/II study of the anti-CD20 CAR-T therapy MB-106 in B-cell malignancies • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer